PT - JOURNAL ARTICLE AU - Uusküla, A AU - Raag, M AU - Barnes, DM AU - Tross, S AU - Talu, A AU - Des Jarlais, D TI - Adapted “Break The Cycle for Avant Garde” Intervention to Reduce Injection Assisting and Promoting Behaviours in People Who Inject Drugs in Tallinn, Estonia: A Pre- Post Trial AID - 10.1101/2022.03.29.22273126 DP - 2022 Jan 01 TA - medRxiv PG - 2022.03.29.22273126 4099 - http://medrxiv.org/content/early/2022/04/02/2022.03.29.22273126.short 4100 - http://medrxiv.org/content/early/2022/04/02/2022.03.29.22273126.full AB - In the context of established and emerging injection drug use epidemics, there is a need to prevent and avert injection drug use. We tested the hypothesis that an individual motivation and skills building counselling, adapted and enhanced from Hunt’s Break the Cycle intervention targeting persons currently injecting drugs would lead to reduction in injection initiation-related behaviours among PWID in Tallinn, Estonia. For this quasi-experimental study, pre-post outcome measures included self-reported promoting behaviours (speaking positively about injecting to non-injectors, injecting in front of non-injectors, offering to give a first injection) and injection initiation behaviours (assisting with or giving a first injection) during the previous 6 months. Of 214 PWID recruited, 189 were retained (88.3%) for the follow-up at 6 months. The proportion of those who had injected in front of non-PWID significantly declined from 15.9% to 8.5%, and reporting assisting with 1st injection from 6.4% to 1.06%. Of the current injectors retained in the study, 17.5% reported not injecting drugs at the follow up. The intervention adapted for the use in the setting of high prevalence of HIV and relatively low prevalence of injection assisting, tested proved to be effective and safe.Competing Interest StatementThe authors have declared no competing interest.Clinical TrialNCT03502525Funding StatementAU - grant # IUT34-17 from the Estonian Ministry of Education and Research, Estonia DDJ - grant 1DP1DA039542 from the National Institutes of Health, USAAuthor DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.Not ApplicableThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Ethical approvals for the studies were obtained from the Ethics Review Board of the University of Tartu, Estonia and from the Mount Sinai Beth Israel Medical Center, and New York University Institutional Review Boards in New York, USAI confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.Not ApplicableI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).Not ApplicableI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.Not ApplicableThe data that support the findings of this study are available on request from the corresponding author, [AU]. The data are not publicly available due to restrictions.